Literature DB >> 16520374

Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.

Yossan-Var Tan1, Alain Couvineau, Samuel Murail, Emilie Ceraudo, Jean-Michel Neumann, Jean-Jacques Lacapère, Marc Laburthe.   

Abstract

The neuropeptide vasoactive intestinal peptide (VIP) strongly impacts on human pathophysiology and does so through interaction with class II G protein-coupled receptors named VIP pituitary adenylate cyclase-activating peptide (PACAP) receptors (VPACs). The molecular nature of VIP binding to receptors remains elusive. In this work, we have docked VIP in the human VPAC1 receptor by the following approach. (i) VIP probes containing photolabile residues in positions 6, 22, and 24 of VIP were used to photolabel the receptor. After receptor cleavage and Edman sequencing of labeled receptor fragments, it was shown that Phe6, Tyr22, and Asn24 of VIP are in contact with Asp107, Gly116, and Cys122 in the N-terminal ectodomain (N-ted) of the receptor, respectively. (ii) The structure of VIP was determined by NMR showing a central alpha helix, a disordered N-terminal His1-Phe6 segment and a 3(10) Ser25-Asn28 helix termination. (iii) A three-dimensional model of the N-ted of hVPAC1 was constructed by using the NMR structure of the N-ted of corticotropin-releasing factor receptor 2beta as a template. As expected, the fold is identified as a short consensus repeat with two antiparallel beta sheets and is stabilized by three disulfide bonds. (iv) Taking into account the constraints provided by photoaffinity, VIP was docked into the hVPAC1 receptor N-ted. The 6-28 fragment of VIP nicely lies in the N-ted C-terminal part, but the N terminus region of VIP is free for interacting with the receptor transmembrane region. The data provide a structural rationale to the proposed two-step activation mechanism of VPAC receptor and more generally of class II G protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520374     DOI: 10.1074/jbc.M513305200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 4.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 5.  Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs.

Authors:  M Dong; C Koole; D Wootten; P M Sexton; L J Miller
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 6.  Activation of G protein-coupled receptors: beyond two-state models and tertiary conformational changes.

Authors:  Paul S-H Park; David T Lodowski; Krzysztof Palczewski
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

7.  Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.

Authors:  Laurence J Miller; Quan Chen; Polo C-H Lam; Delia I Pinon; Patrick M Sexton; Ruben Abagyan; Maoqing Dong
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

8.  Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain.

Authors:  Mi Jin Moon; Yoo-Na Lee; Sumi Park; Arfaxad Reyes-Alcaraz; Jong-Ik Hwang; Robert Peter Millar; Han Choe; Jae Young Seong
Journal:  J Biol Chem       Date:  2015-01-05       Impact factor: 5.157

9.  Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.

Authors:  Quan Chen; Delia I Pinon; Laurence J Miller; Maoqing Dong
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

10.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Authors:  Chaohong Sun; Danying Song; Rachel A Davis-Taber; Leo W Barrett; Victoria E Scott; Paul L Richardson; Ana Pereda-Lopez; Marie E Uchic; Larry R Solomon; Marc R Lake; Karl A Walter; Philip J Hajduk; Edward T Olejniczak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.